Publications by authors named "J P van Kuijk"
In patients with chronic thromboembolic pulmonary hypertension (CTEPH) who undergo balloon pulmonary angioplasty (BPA), pretreatment with PH-targeted medical therapy may be beneficial to improve clinical parameters and pulmonary hemodynamics. This study aims to describe clinical results of PH-targeted therapy prior to BPA. All consecutive patients with CTEPH who underwent BPA treatment were selected from our CTEPH database.
View Article and Find Full Text PDFBackground: Patients with refractory angina are often ineligible for revascularization and have poor quality of life despite optimal medical therapy. The coronary sinus (CS) Reducer (Shockwave Medical Inc) was safe and effective in the treatment of refractory angina in the COSIRA (Coronary Sinus Reducer for Treatment of Refractory Angina) randomized sham-controlled trial.
Objectives: This study sought to perform the primary endpoint analysis of the complete REDUCER-I (An Observational Study of the Neovasc Reducer System) study cohort.
High-risk features in non-culprit lesions and clinical outcome after NSTEMI versus STEMI.
Eur Heart J Cardiovasc Imaging
November 2024
Article Synopsis
- The study investigates the impact of non-culprit (NC) lesions in patients with NSTEMI compared to those with STEMI, focusing on high-risk plaque features and their influence on clinical outcomes.
- Among 438 patients, both NSTEMI and STEMI groups showed similar prevalence of high-risk plaques, but NSTEMI patients had a higher rate of major adverse cardiovascular events (MACE) after two years.
- The findings suggest that the presence of high-risk plaques in NC lesions is critical for dictating future cardiovascular events, indicating the need for further research on effective revascularization strategies in NSTEMI patients.
Article Synopsis
- The study aimed to compare the safety and effectiveness of two types of stents in patients at high bleeding risk who were undergoing abbreviated dual antiplatelet therapy after coronary stenting: the ultrathin-strut Supraflex Cruz stent and the thin-strut Ultimaster Tansei stent.
- A total of 741 patients were enrolled in a randomized trial where they received one of the two stents, and the primary outcome measured was a combination of serious adverse events over one year.
- Results showed that 15.4% of patients with the Supraflex Cruz stent experienced adverse outcomes compared to 17.1% with the Ultimaster Tansei stent, indicating a potential slight difference
Article Synopsis
- Recurrent events after myocardial infarction (MI) often arise from non-flow limiting lesions, which may differ between sexes, prompting this study to investigate these potential differences among MI patients.
- The study examined 420 patients, finding that female patients had longer NC lesions and smaller lumen areas and diameters, as well as thinner fibrous caps compared to male patients.
- Despite females exhibiting more high-risk plaque characteristics, both genders experienced similar rates of major cardiovascular events at two years, suggesting the need for further research on long-term outcomes related to these differences.